Assessment of long-term antibody persistence after a booster dose of GSK Biologicals' Hib and meningococcal C vaccine (Menitorix) 471266 given at 12-15 months of age to subjects primed with 3 doses of Menitorix at 2, 3, 4 months of age.

Trial Profile

Assessment of long-term antibody persistence after a booster dose of GSK Biologicals' Hib and meningococcal C vaccine (Menitorix) 471266 given at 12-15 months of age to subjects primed with 3 doses of Menitorix at 2, 3, 4 months of age.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs DTaP poliovirus vaccine (Primary) ; Hib-DTaP-poliovirus vaccine (Primary) ; Hib-meningococcal vaccine group C conjugate (Primary) ; Meningococcal vaccine group C conjugate (Primary) ; Measles mumps and rubella virus vaccine
  • Indications Diphtheria; Haemophilus infections; Meningococcal group C infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 Sep 2011 Actual end date changed from Oct 2007 to May 2010 as reported by ClinicalTrials.gov.
    • 13 Jan 2010 Additional lead trial investigator identified as reported by United Kingdom Clinical Research Network.
    • 13 Jan 2010 New source identified and integrated (United Kingdom Clinical Research Network 7814).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top